The major histocompatibility complex class I (MHC-I) antigen presentation pathway is central to the adaptive immune response. In this process, intracellular proteins are degraded primarily by the ...

MHC Class II molecules are integral to the adaptive immune response, serving as specialised antigen-presenting proteins on the surface of professional antigen-presenting cells. They bind peptide ...

In a recent article posted to the bioRxiv* preprint server, researchers demonstrated the sarbecovirus open reading frame 7a (ORF7a)-induced hindrance of the antigen presentation by the major ...

Many cancers evade immune rejection by suppressing major histocompatibility class I (MHC-I) antigen processing and presentation (AgPP). Such cancers do not respond to immune checkpoint inhibitor ...

This is a preview. Log in through your library . Abstract Combining multiple therapeutic strategies in NRAS/BRAF mutant melanoma—namely MEK/BRAF kinase inhibitors, immune checkpoint inhibitors (ICIs), ...

CAMBRIDGE, MA -- A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease. In the ...

A large-scale screen of tuberculosis proteins has revealed several possible antigens that could be developed as a new vaccine for TB, the world’s deadliest infectious disease. In the new study, a team ...

Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes through targeted T-cell activation.